

Bibliography

- [1] U. Broome et al. “Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis”. In: *Gut* 38.4 (1996), pp. 610–5. ISSN: 0017-5749 (Print) 0017-5749 (Linking). URL: <http://www.ncbi.nlm.nih.gov/pubmed/8707097>.
- [2] Elizabeth C Goode et al. “Factors associated with outcomes of patients with primary sclerosing cholangitis and development and validation of a risk scoring system”. In: *Hepatology* 69.5 (2019), pp. 2120–2135.
- [3] Edward Alabraba et al. “A re-evaluation of the risk factors for the recurrence of primary sclerosing cholangitis in liver allografts”. In: *Liver Transplantation* 15.3 (2009), pp. 330–340.
- [4] A. Bergquist et al. “Hepatic and extrahepatic malignancies in primary sclerosing cholangitis”. In: *J Hepatol* 36.3 (2002), pp. 321–7. ISSN: 0168-8278 (Print) 0168-8278 (Linking). URL: <http://www.ncbi.nlm.nih.gov/pubmed/11867174>.
- [5] M. M. Claessen et al. “High lifetime risk of cancer in primary sclerosing cholangitis”. In: *J Hepatol* 50.1 (2009), pp. 158–64. ISSN: 0168-8278 (Print) 0168-8278 (Linking). DOI: 10.1016/j.jhep.2008.08.013. URL: <http://www.ncbi.nlm.nih.gov/pubmed/19012991>.
- [6] Martin Blachier et al. “The burden of liver disease in Europe: a review of available epidemiological data”. In: *Journal of hepatology* 58.3 (2013), pp. 593–608.
- [7] S Charman, L Copley, C Tovikkai, et al. *UK liver transplant audit (NHS Blood and Transplant)*. 2012. 2015.
- [8] H. Sano et al. “Clinical characteristics of inflammatory bowel disease associated with primary sclerosing cholangitis”. In: *J Hepatobiliary Pancreat Sci* 18.2 (2011), pp. 154–61. ISSN: 1868-6982 (Electronic). DOI: 10.1007/s00534-010-0319-8. URL: <http://www.ncbi.nlm.nih.gov/pubmed/20740366>.

- [9] B. D. Ye et al. “Clinical characteristics of ulcerative colitis associated with primary sclerosing cholangitis in Korea”. In: *Inflamm Bowel Dis* 17.9 (2011), pp. 1901–6. ISSN: 1536-4844 (Electronic) 1078-0998 (Linking). DOI: 10.1002/ibd.21569. URL: <http://www.ncbi.nlm.nih.gov/pubmed/21830268>.
- [10] K. Boonstra et al. “Primary sclerosing cholangitis is associated with a distinct phenotype of inflammatory bowel disease”. In: *Inflamm Bowel Dis* 18.12 (2012), pp. 2270–6. ISSN: 1536-4844 (Electronic) 1078-0998 (Linking). DOI: 10.1002/ibd.22938. URL: <http://www.ncbi.nlm.nih.gov/pubmed/22407885>.
- [11] Jr. Loftus E. V. et al. “PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis”. In: *Gut* 54.1 (2005), pp. 91–6. ISSN: 0017-5749 (Print) 0017-5749 (Linking). DOI: 10.1136/gut.2004.046615. URL: <http://www.ncbi.nlm.nih.gov/pubmed/15591511>.
- [12] T. J. Weismuller et al. “Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis”. In: *Gastroenterology* (2017). ISSN: 1528-0012 (Electronic) 0016-5085 (Linking). DOI: 10.1053/j.gastro.2017.02.038. URL: <https://www.ncbi.nlm.nih.gov/pubmed/28274849>.
- [13] E Björnsson et al. “Patients with small duct primary sclerosing cholangitis have a favourable long term prognosis”. In: *Gut* 51.5 (2002), pp. 731–735.
- [14] Einar Björnsson et al. “Primary sclerosing cholangitis associated with elevated immunoglobulinG4: clinical characteristics and response to therapy”. In: *American journal of therapeutics* 18.3 (2011), pp. 198–205.
- [15] U. Broome et al. “Primary sclerosing cholangitis and ulcerative colitis: evidence for increased neoplastic potential”. In: *Hepatology* 22.5 (1995), pp. 1404–8. ISSN: 0270-9139 (Print) 0270-9139 (Linking). URL: <http://www.ncbi.nlm.nih.gov/pubmed/7590655>.
- [16] U. Beuers. “Drug insight: Mechanisms and sites of action of ursodeoxycholic acid in cholestasis”. In: *Nat Clin Pract Gastroenterol Hepatol* 3.6 (2006), pp. 318–28. ISSN: 1743-4378 (Print) 1743-4378 (Linking). DOI: 10.1038/ncpgasthep0521. URL: <http://www.ncbi.nlm.nih.gov/pubmed/16741551>.
- [17] Elizabeth C Goode and Simon M Rushbrook. “A review of the medical treatment of primary sclerosing cholangitis in the 21st century”. In: *Therapeutic advances in chronic disease* 7.1 (2016), pp. 68–85.
- [18] William G Hill, Michael E Goddard, and Peter M Visscher. “Data and theory point to mainly additive genetic variance for complex traits”. In: *PLoS genetics* 4.2 (2008), e1000008.

- [19] EA Stahl et al. “Diabetes Genetics Replication and Meta-analysis Consortium; Myocardial Infarction Genetics Consortium (2012). Bayesian inference analyses of the polygenic architecture of rheumatoid arthritis”. In: *Nat. Genet* 44 (), pp. 483–489.
- [20] Björn Lindkvist et al. “Incidence and prevalence of primary sclerosing cholangitis in a defined adult population in Sweden”. In: *Hepatology* 52.2 (2010), pp. 571–577.
- [21] RAKESH KOCHHAR et al. “Primary sclerosing cholangitis: an experience from India”. In: *Journal of gastroenterology and hepatology* 11.5 (1996), pp. 429–433.
- [22] Tiing Leong Ang et al. “Clinical profile of primary sclerosing cholangitis in Singapore”. In: *Journal of gastroenterology and hepatology* 17.8 (2002), pp. 908–913.
- [23] Annika Bergquist et al. “Increased prevalence of primary sclerosing cholangitis among first-degree relatives”. In: *Journal of hepatology* 42.2 (2005), pp. 252–256.
- [24] Annika Bergquist et al. “Increased risk of primary sclerosing cholangitis and ulcerative colitis in first-degree relatives of patients with primary sclerosing cholangitis”. In: *Clinical gastroenterology and hepatology* 6.8 (2008), pp. 939–943.
- [25] Ina Marie Andersen et al. “Effects of coffee consumption, smoking, and hormones on risk for primary sclerosing cholangitis”. In: *Clinical Gastroenterology and Hepatology* 12.6 (2014), pp. 1019–1028.
- [26] Kristin G Ardlie, Leonid Kruglyak, and Mark Seielstad. “Patterns of linkage disequilibrium in the human genome”. In: *Nature Reviews Genetics* 3.4 (2002), p. 299.
- [27] Mark J Daly et al. “High-resolution haplotype structure in the human genome”. In: *Nature genetics* 29.2 (2001), p. 229.
- [28] Jeffrey C Barrett and Lon R Cardon. “Evaluating coverage of genome-wide association studies”. In: *Nature genetics* 38.6 (2006), p. 659.
- [29] International HapMap Consortium et al. “A second generation human haplotype map of over 3.1 million SNPs”. In: *Nature* 449.7164 (2007), p. 851.
- [30] Clive J Hoggart et al. “Genome-wide significance for dense SNP and resequencing data”. In: *Genetic Epidemiology: The Official Publication of the International Genetic Epidemiology Society* 32.2 (2008), pp. 179–185.
- [31] Peter K Gregersen and Lina M Olsson. “Recent advances in the genetics of autoimmune disease”. In: *Annual review of immunology* 27 (2009), pp. 363–391.
- [32] Alexandra Zhernakova, Cleo C Van Diemen, and Cisca Wijmenga. “Detecting shared pathogenesis from the shared genetics of immune-related diseases”. In: *Nature Reviews Genetics* 10.1 (2009), p. 43.

- [33] Brendan J Keating et al. “Concept, design and implementation of a cardiovascular gene-centric 50 k SNP array for large-scale genomic association studies”. In: *PloS one* 3.10 (2008).
- [34] Adrian Cortes and Matthew A Brown. “Promise and pitfalls of the ImmunoChip”. In: *Arthritis research & therapy* 13.1 (2011), p. 101.
- [35] David B Goldstein et al. “Sequencing studies in human genetics: design and interpretation”. In: *Nature Reviews Genetics* 14.7 (2013), p. 460.
- [36] Jonathan K Pritchard. “Are rare variants responsible for susceptibility to complex diseases?” In: *The American Journal of Human Genetics* 69.1 (2001), pp. 124–137.
- [37] Espen Melum et al. “Genome-wide association analysis in primary sclerosing cholangitis identifies two non-HLA susceptibility loci”. In: *Nature genetics* 43.1 (2011), p. 17.
- [38] Trine Folseraas et al. “Extended analysis of a genome-wide association study in primary sclerosing cholangitis detects multiple novel risk loci”. In: *Journal of hepatology* 57.2 (2012), pp. 366–375.
- [39] David Ellinghaus et al. “Genome-wide association analysis in Primary sclerosing cholangitis and ulcerative colitis identifies risk loci at GPR35 and TCF4”. In: *Hepatology* 58.3 (2013), pp. 1074–1083.
- [40] Jimmy Z Liu et al. “Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis”. In: *Nature genetics* 45.6 (2013), p. 670.
- [41] David Ellinghaus et al. “Analysis of five chronic inflammatory diseases identifies 27 new associations and highlights disease-specific patterns at shared loci”. In: *Nature genetics* 48.5 (2016), p. 510.
- [42] Sun-Gou Ji et al. “Genome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel disease”. In: *Nature genetics* 49.2 (2017), p. 269.
- [43] John Trowsdale and Julian C Knight. “Major histocompatibility complex genomics and human disease”. In: *Annual review of genomics and human genetics* 14 (2013), pp. 301–323.
- [44] T. H. Karlsen et al. “Genome-wide association analysis in primary sclerosing cholangitis”. In: *Gastroenterology* 138.3 (2010), pp. 1102–11. ISSN: 1528-0012 (Electronic) 0016-5085 (Linking). DOI: 10.1053/j.gastro.2009.11.046. URL: <http://www.ncbi.nlm.nih.gov/pubmed/19944697>.

- [45] J. Z. Liu et al. “Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis”. In: *Nat Genet* 45.6 (2013), pp. 670–5. ISSN: 1546-1718 (Electronic) 1061-4036 (Linking). DOI: 10.1038/ng.2616. URL: <http://www.ncbi.nlm.nih.gov/pubmed/23603763>.
- [46] Christopher E Lowe et al. “Large-scale genetic fine mapping and genotype-phenotype associations implicate polymorphism in the IL2RA region in type 1 diabetes”. In: *Nature genetics* 39.9 (2007), p. 1074.
- [47] Eli A Stahl et al. “Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci”. In: *Nature genetics* 42.6 (2010), p. 508.
- [48] Edward J Carr et al. “Contrasting genetic association of IL2RA with SLE and ANCA-associated vasculitis”. In: *BMC Medical Genetics* 10.1 (2009), p. 22.
- [49] Jinguo Wang, Linda S Wicker, and Pere Santamaria. “IL-2 and its high-affinity receptor: genetic control of immunoregulation and autoimmunity”. In: *Seminars in immunology*. Vol. 21. 6. Elsevier. 2009, pp. 363–371.
- [50] Li Lu et al. “Hippo signaling is a potent in vivo growth and tumor suppressor pathway in the mammalian liver”. In: *Proceedings of the National Academy of Sciences* 107.4 (2010), pp. 1437–1442.
- [51] Koko Katagiri et al. “Mst1 controls lymphocyte trafficking and interstitial motility within lymph nodes”. In: *The EMBO journal* 28.9 (2009), pp. 1319–1331.
- [52] Tarana Singh Dang et al. “Defective leukocyte adhesion and chemotaxis contributes to combined immunodeficiency in humans with autosomal recessive MST1 deficiency”. In: *Journal of clinical immunology* 36.2 (2016), pp. 117–122.
- [53] Allister J Grant et al. “MAdCAM-1 expressed in chronic inflammatory liver disease supports mucosal lymphocyte adhesion to hepatic endothelium (MAdCAM-1 in chronic inflammatory liver disease)”. In: *Hepatology* 33.5 (2001), pp. 1065–1072.
- [54] F Häuser et al. “Macrophage-stimulating protein polymorphism rs3197999 is associated with a gain of function: implications for inflammatory bowel disease”. In: *Genes and immunity* 13.4 (2012), p. 321.
- [55] PHILIPPE Goyette et al. “Gene-centric association mapping of chromosome 3p implicates MST1 in IBD pathogenesis”. In: *Mucosal Immunology* 1.2 (2008), p. 131.
- [56] Hailiang Huang et al. “Fine-mapping inflammatory bowel disease loci to single-variant resolution”. In: *Nature* 547.7662 (2017), p. 173.
- [57] Silvia Fallarini et al. “Expression of functional GPR35 in human iNKT cells”. In: *Biochemical and biophysical research communications* 398.3 (2010), pp. 420–425.

- [58] Jinghong Wang et al. “Kynurenic acid as a ligand for orphan G protein-coupled receptor GPR35”. In: *Journal of Biological Chemistry* 281.31 (2006), pp. 22021–22028.
- [59] Piotr Paluszkiwicz et al. “High concentration of kynurenic acid in bile and pancreatic juice”. In: *Amino acids* 37.4 (2009), pp. 637–641.
- [60] Katrina M de Lange et al. “Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease”. In: *Nature genetics* 49.2 (2017), p. 256.
- [61] Caroline M Forrest et al. “Purine, kynurenine, neopterin and lipid peroxidation levels in inflammatory bowel disease”. In: *Journal of biomedical science* 9.5 (2002), pp. 436–442.
- [62] Georg Schneditz et al. “GPR35 promotes glycolysis, proliferation, and oncogenic signaling by engaging with the sodium potassium pump”. In: *Sci. Signal.* 12.562 (2019), eaau9048.
- [63] Marta Wagner et al. “Polymorphisms in CD28, CTLA-4, CD80 and CD86 genes may influence the risk of multiple sclerosis and its age of onset”. In: *Journal of neuroimmunology* 288 (2015), pp. 79–86.
- [64] Evaggelia Liaskou et al. “Loss of CD28 expression by liver-infiltrating T cells contributes to pathogenesis of primary sclerosing cholangitis”. In: *Gastroenterology* 147.1 (2014), pp. 221–232.
- [65] Kanji Wakabayashi et al. “IL-2 receptor α -/- mice and the development of primary biliary cirrhosis”. In: *Hepatology* 44.5 (2006), pp. 1240–1249.
- [66] X Bo et al. “Tumour necrosis factor α impairs function of liver derived T lymphocytes and natural killer cells in patients with primary sclerosing cholangitis”. In: *Gut* 49.1 (2001), pp. 131–141.
- [67] Marcial Sebode et al. “Reduced FOXP3+ regulatory T cells in patients with primary sclerosing cholangitis are associated with IL2RA gene polymorphisms”. In: *Journal of hepatology* 60.5 (2014), pp. 1010–1016.
- [68] Herbert G Kasler et al. “Histone deacetylase 7 regulates cell survival and TCR signaling in CD4/CD8 double-positive thymocytes”. In: *The Journal of Immunology* (2011), p. 1001179.
- [69] Richard N Hanna et al. “The transcription factor NR4A1 (Nur77) controls bone marrow differentiation and the survival of Ly6C- monocytes”. In: *Nature immunology* 12.8 (2011), p. 778.

- [70] Franck Dequiedt et al. “Phosphorylation of histone deacetylase 7 by protein kinase D mediates T cell receptor–induced Nur77 expression and apoptosis”. In: *Journal of Experimental Medicine* 201.5 (2005), pp. 793–804.
- [71] Franck Dequiedt et al. “HDAC7, a thymus-specific class II histone deacetylase, regulates Nur77 transcription and TCR-mediated apoptosis”. In: *Immunity* 18.5 (2003), pp. 687–698.
- [72] Luke Jostins et al. “Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease”. In: *Nature* 491.7422 (2012), p. 119.
- [73] Jimmy Z Liu et al. “Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations”. In: *Nature genetics* 47.9 (2015), p. 979.
- [74] Yukinori Okada et al. “HLA-Cw* 1202-B* 5201-DRB1* 1502 haplotype increases risk for ulcerative colitis but reduces risk for Crohn’s disease”. In: *Gastroenterology* 141.3 (2011), pp. 864–871.
- [75] Natalie L Berntsen et al. “Association between HLA haplotypes and increased serum levels of IgG4 in patients with primary sclerosing cholangitis”. In: *Gastroenterology* 148.5 (2015), pp. 924–927.
- [76] Sigrid Næss et al. “Small duct primary sclerosing cholangitis without inflammatory bowel disease is genetically different from large duct disease”. In: *Liver International* 34.10 (2014), pp. 1488–1495.
- [77] Eric J Kunkel et al. “Lymphocyte CC chemokine receptor 9 and epithelial thymus-expressed chemokine (TECK) expression distinguish the small intestinal immune compartment: epithelial expression of tissue-specific chemokines as an organizing principle in regional immunity”. In: *Journal of Experimental Medicine* 192.5 (2000), pp. 761–768.
- [78] Palak J Trivedi et al. “Intestinal CCL25 expression is increased in colitis and correlates with inflammatory activity”. In: *Journal of autoimmunity* 68 (2016), pp. 98–104.
- [79] Kenneth J Hillan et al. “Expression of the mucosal vascular addressin, MAdCAM-1, in inflammatory liver disease”. In: *Liver* 19.6 (1999), pp. 509–518.
- [80] Bertus Eksteen et al. “Hepatic endothelial CCL25 mediates the recruitment of CCR9+ gut-homing lymphocytes to the liver in primary sclerosing cholangitis”. In: *Journal of Experimental Medicine* 200.11 (2004), pp. 1511–1517.

- [81] K. M. de Lange et al. “Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease”. In: *Nat Genet* 49.2 (2017), pp. 256–261. ISSN: 1546-1718 (Electronic) 1061-4036 (Linking). DOI: 10.1038/ng.3760. URL: <https://www.ncbi.nlm.nih.gov/pubmed/28067908>.
- [82] B. P. Fairfax et al. “Innate immune activity conditions the effect of regulatory variants upon monocyte gene expression”. In: *Science* 343.6175 (2014), p. 1246949. ISSN: 1095-9203 (Electronic) 0036-8075 (Linking). DOI: 10.1126/science.1246949. URL: <http://www.ncbi.nlm.nih.gov/pubmed/24604202>.
- [83] Brian G Feagan et al. “Vedolizumab as induction and maintenance therapy for ulcerative colitis”. In: *New England Journal of Medicine* 369.8 (2013), pp. 699–710.
- [84] William J Sandborn et al. “Vedolizumab as induction and maintenance therapy for Crohn’s disease”. In: *New England Journal of Medicine* 369.8 (2013), pp. 711–721.
- [85] CS Tse et al. “Effects of vedolizumab, adalimumab and infliximab on biliary inflammation in individuals with primary sclerosing cholangitis and inflammatory bowel disease”. In: *Alimentary pharmacology & therapeutics* 48.2 (2018), pp. 190–195.
- [86] B Christensen et al. “Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease”. In: *Alimentary pharmacology & therapeutics* 47.6 (2018), pp. 753–762.
- [87] Eva Kristine Klemsdal Henriksen et al. “Gut and liver T-cells of common clonal origin in primary sclerosing cholangitis-inflammatory bowel disease”. In: *Journal of hepatology* 66.1 (2017), pp. 116–122.
- [88] Ulrich Beuers et al. “The biliary HCO₃⁻ umbrella: a unifying hypothesis on pathogenetic and therapeutic aspects of fibrosing cholangiopathies”. In: *Hepatology* 52.4 (2010), pp. 1489–1496.
- [89] Olivier Chazouillères. “Primary sclerosing cholangitis and bile acids”. In: *Clinics and research in hepatology and gastroenterology* 36 (2012), S21–S25.
- [90] Peter Fickert et al. “Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice”. In: *Gastroenterology* 127.1 (2004), pp. 261–274.
- [91] Tom H Karlsen et al. “Genome-wide association analysis in primary sclerosing cholangitis”. In: *Gastroenterology* 138.3 (2010), pp. 1102–1111.
- [92] Keith D Lindor et al. “High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis”. In: *Hepatology* 50.3 (2009), pp. 808–814.

- [93] Emmanouil Sinakos et al. “Bile acid changes after high-dose ursodeoxycholic acid treatment in primary sclerosing cholangitis: Relation to disease progression”. In: *Hepatology* 52.1 (2010), pp. 197–203.
- [94] A. F. Hofmann et al. “Novel biotransformation and physiological properties of norursodeoxycholic acid in humans”. In: *Hepatology* 42.6 (2005), pp. 1391–8. ISSN: 0270-9139 (Print) 0270-9139 (Linking). DOI: 10.1002/hep.20943. URL: <http://www.ncbi.nlm.nih.gov/pubmed/16317695>.
- [95] Michael Trauner et al. “Potential of nor-ursodeoxycholic acid in cholestatic and metabolic disorders”. In: *Digestive Diseases* 33.3 (2015), pp. 433–439.
- [96] Peter Fickert et al. “norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis”. In: *Journal of hepatology* 67.3 (2017), pp. 549–558.
- [97] Kris V Kowdley et al. “A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis”. In: *Hepatology* 67.5 (2018), pp. 1890–1902.
- [98] Valerio Pontecorvi, Marco Carbone, and Pietro Invernizzi. “The “gut microbiota” hypothesis in primary sclerosing cholangitis”. In: *Annals of translational medicine* 4.24 (2016).
- [99] Andrew J Macpherson and Karen Smith. “Mesenteric lymph nodes at the center of immune anatomy”. In: *Journal of Experimental Medicine* 203.3 (2006), pp. 497–500.
- [100] Malin EV Johansson et al. “Bacteria penetrate the normally impenetrable inner colon mucus layer in both murine colitis models and patients with ulcerative colitis”. In: *Gut* 63.2 (2014), pp. 281–291.
- [101] Andrea Michielan and Renata D’Incà. “Intestinal permeability in inflammatory bowel disease: pathogenesis, clinical evaluation, and therapy of leaky gut”. In: *Mediators of inflammation* 2015 (2015).
- [102] Rolf Olsson et al. “Bile duct bacterial isolates in primary sclerosing cholangitis: a study of explanted livers”. In: *Journal of hepatology* 28.3 (1998), pp. 426–432.
- [103] Martti Färkkilä et al. “Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: A randomized placebo-controlled trial”. In: *Hepatology* 40.6 (2004), pp. 1379–1386.
- [104] Iris C Steenstraten et al. “Systematic review with meta-analysis: risk factors for recurrent primary sclerosing cholangitis after liver transplantation”. In: *Alimentary pharmacology & therapeutics* 49.6 (2019), pp. 636–643.
- [105] Aleksandar D Kostic, Ramnik J Xavier, and Dirk Gevers. “The microbiome in inflammatory bowel disease: current status and the future ahead”. In: *Gastroenterology* 146.6 (2014), pp. 1489–1499.

- [106] Marie Joossens et al. “Dysbiosis of the faecal microbiota in patients with Crohn’s disease and their unaffected relatives”. In: *Gut* 60.5 (2011), pp. 631–637.
- [107] Harry Sokol et al. “Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients”. In: *Proceedings of the National Academy of Sciences* 105.43 (2008), pp. 16731–16736.
- [108] Kathleen Machiels et al. “A decrease of the butyrate-producing species *Roseburia hominis* and *Faecalibacterium prausnitzii* defines dysbiosis in patients with ulcerative colitis”. In: *Gut* 63.8 (2014), pp. 1275–1283.
- [109] João Sabino et al. “Primary sclerosing cholangitis is characterised by intestinal dysbiosis independent from IBD”. In: *Gut* 65.10 (2016), pp. 1681–1689.
- [110] Williams Turpin et al. “Association of host genome with intestinal microbial composition in a large healthy cohort”. In: *Nature genetics* 48.11 (2016), p. 1413.
- [111] Marc Jan Bonder et al. “The effect of host genetics on the gut microbiome”. In: *Nature genetics* 48.11 (2016), p. 1407.
- [112] Dan Knights et al. “Complex host genetics influence the microbiome in inflammatory bowel disease”. In: *Genome medicine* 6.12 (2014), p. 107.
- [113] Sarah L Spain and Jeffrey C Barrett. “Strategies for fine-mapping complex traits”. In: *Human molecular genetics* 24.R1 (2015), R111–R119.
- [114] Harm-Jan Westra et al. “Fine-mapping and functional studies highlight potential causal variants for rheumatoid arthritis and type 1 diabetes”. In: *Nature genetics* 50.10 (2018), pp. 1366–1374.
- [115] Matthew T Maurano et al. “Systematic localization of common disease-associated variation in regulatory DNA”. In: *Science* (2012), p. 1222794.
- [116] William Cookson et al. “Mapping complex disease traits with global gene expression”. In: *Nature Reviews Genetics* 10.3 (2009), p. 184.
- [117] Dan L Nicolae et al. “Trait-associated SNPs are more likely to be eQTLs: annotation to enhance discovery from GWAS”. In: *PLoS genetics* 6.4 (2010), e1000888.
- [118] Harm-Jan Westra et al. “Systematic identification of trans eQTLs as putative drivers of known disease associations”. In: *Nature genetics* 45.10 (2013), p. 1238.
- [119] Alexandra C Nica et al. “Candidate causal regulatory effects by integration of expression QTLs with complex trait genetic associations”. In: *PLoS genetics* 6.4 (2010), e1000895.
- [120] Barbara E Stranger et al. “Population genomics of human gene expression”. In: *Nature genetics* 39.10 (2007), p. 1217.

- [121] Federico Innocenti et al. “Identification, replication, and functional fine-mapping of expression quantitative trait loci in primary human liver tissue”. In: *PLoS genetics* 7.5 (2011), e1002078.
- [122] Barbara E Stranger et al. “Relative impact of nucleotide and copy number variation on gene expression phenotypes”. In: *Science* 315.5813 (2007), pp. 848–853.
- [123] Jean-Baptiste Veyrieras et al. “High-resolution mapping of expression-QTLs yields insight into human gene regulation”. In: *PLoS genetics* 4.10 (2008), e1000214.
- [124] Jacob F Degner et al. “DNase I sensitivity QTLs are a major determinant of human expression variation”. In: *Nature* 482.7385 (2012), p. 390.
- [125] Christopher D Brown, Lara M Mangravite, and Barbara E Engelhardt. “Integrative modeling of eQTLs and cis-regulatory elements suggests mechanisms underlying cell type specificity of eQTLs”. In: *PLoS genetics* 9.8 (2013), e1003649.
- [126] Scott Smemo et al. “Obesity-associated variants within FTO form long-range functional connections with IRX3”. In: *Nature* 507.7492 (2014), p. 371.
- [127] Rudolf SN Fehrmann et al. “Trans-eQTLs reveal that independent genetic variants associated with a complex phenotype converge on intermediate genes, with a major role for the HLA”. In: *PLoS genetics* 7.8 (2011), e1002197.
- [128] Matthias Heinig et al. “A trans-acting locus regulates an anti-viral expression network and type 1 diabetes risk”. In: *Nature* 467.7314 (2010), p. 460.
- [129] Benjamin P Fairfax et al. “Genetics of gene expression in primary immune cells identifies cell type-specific master regulators and roles of HLA alleles”. In: *Nature genetics* 44.5 (2012), p. 502.
- [130] Benjamin P Fairfax et al. “Innate immune activity conditions the effect of regulatory variants upon monocyte gene expression”. In: *Science* 343.6175 (2014), p. 1246949.
- [131] Alice Gerrits et al. “Expression quantitative trait loci are highly sensitive to cellular differentiation state”. In: *PLoS genetics* 5.10 (2009), e1000692.
- [132] Erin L Heinzen et al. “Tissue-specific genetic control of splicing: implications for the study of complex traits”. In: *PLoS biology* 6.12 (2008), e1000001.
- [133] Antigone S Dimas et al. “Common regulatory variation impacts gene expression in a cell type-dependent manner”. In: *Science* 325.5945 (2009), pp. 1246–1250.
- [134] Kaur Alasoo et al. “Shared genetic effects on chromatin and gene expression indicate a role for enhancer priming in immune response”. In: *Nature genetics* 50.3 (2018), p. 424.
- [135] Bradley E Bernstein, Alexander Meissner, and Eric S Lander. “The mammalian epigenome”. In: *Cell* 128.4 (2007), pp. 669–681.

- [136] Zhenhai Zhang and B Franklin Pugh. “High-resolution genome-wide mapping of the primary structure of chromatin”. In: *Cell* 144.2 (2011), pp. 175–186.
- [137] John Newell-Price, Adrian JL Clark, and Peter King. “DNA methylation and silencing of gene expression”. In: *Trends in Endocrinology & Metabolism* 11.4 (2000), pp. 142–148.
- [138] Egor Prokhortchouk and Pierre-Antoine Defossez. “The cell biology of DNA methylation in mammals”. In: *Biochimica Et Biophysica Acta (BBA)-Molecular Cell Research* 1783.11 (2008), pp. 2167–2173.
- [139] Lanlan Shen et al. “Genome-wide profiling of DNA methylation reveals a class of normally methylated CpG island promoters”. In: *PLoS genetics* 3.10 (2007), e181.
- [140] Robert Illingworth et al. “A novel CpG island set identifies tissue-specific methylation at developmental gene loci”. In: *PLoS biology* 6.1 (2008), e22.
- [141] Tina Branscombe Miranda and Peter A Jones. “DNA methylation: the nuts and bolts of repression”. In: *Journal of cellular physiology* 213.2 (2007), pp. 384–390.
- [142] Michael Weber and Dirk Schübeler. “Genomic patterns of DNA methylation: targets and function of an epigenetic mark”. In: *Current opinion in cell biology* 19.3 (2007), pp. 273–280.
- [143] Eric Hervouet, Francois M Vallette, and Pierre-Francois Cartron. “Dnmt3/transcription factor interactions as crucial players in targeted DNA methylation”. In: *Epigenetics* 4.7 (2009), pp. 487–499.
- [144] Paul A Wade. “Methyl CpG binding proteins: coupling chromatin architecture to gene regulation”. In: *Oncogene* 20.24 (2001), p. 3166.
- [145] Allan F McRae et al. “Identification of 55,000 replicated DNA methylation QTL”. In: *Scientific Reports* 8.1 (2018), p. 17605.
- [146] Marc Jan Bonder et al. “Disease variants alter transcription factor levels and methylation of their binding sites”. In: *Nature genetics* 49.1 (2017), p. 131.
- [147] Mark C Genovese et al. “Abatacept for rheumatoid arthritis refractory to tumor necrosis factor α inhibition”. In: *New England Journal of Medicine* 353.11 (2005), pp. 1114–1123.
- [148] Yukinori Okada et al. “Genetics of rheumatoid arthritis contributes to biology and drug discovery”. In: *Nature* 506.7488 (2014), p. 376.
- [149] William J Sandborn et al. “Ustekinumab induction and maintenance therapy in refractory Crohn’s disease”. In: *New England Journal of Medicine* 367.16 (2012), pp. 1519–1528.

- [150] Andre Franke et al. “Genome-wide meta-analysis increases to 71 the number of confirmed Crohn’s disease susceptibility loci”. In: *Nature genetics* 42.12 (2010), p. 1118.
- [151] Robert M Plenge, Edward M Scolnick, and David Altshuler. “Validating therapeutic targets through human genetics”. In: *Nature reviews Drug discovery* 12.8 (2013), pp. 581–594.
- [152] Matthew R Nelson et al. “The support of human genetic evidence for approved drug indications”. In: *Nature genetics* 47.8 (2015), p. 856.
- [153] UK10K consortium et al. “The UK10K project identifies rare variants in health and disease”. In: *Nature* 526.7571 (2015), p. 82.
- [154] 1000 Genomes Project Consortium et al. “An integrated map of genetic variation from 1,092 human genomes”. In: *Nature* 491.7422 (2012), p. 56.
- [155] Gleb Kichaev et al. “Integrating functional data to prioritize causal variants in statistical fine-mapping studies”. In: *PLoS genetics* 10.10 (2014).
- [156] Farhad Hormozdiari et al. “Identifying causal variants at loci with multiple signals of association”. In: *Genetics* 198.2 (2014), pp. 497–508.
- [157] Wenan Chen et al. “Fine mapping causal variants with an approximate Bayesian method using marginal test statistics”. In: *Genetics* 200.3 (2015), pp. 719–736.
- [158] Christian Benner et al. “FINEMAP: efficient variable selection using summary data from genome-wide association studies”. In: *Bioinformatics* 32.10 (2016), pp. 1493–1501.
- [159] Christian Benner et al. “Prospects of fine-mapping trait-associated genomic regions by using summary statistics from genome-wide association studies”. In: *The American Journal of Human Genetics* 101.4 (2017), pp. 539–551.
- [160] Chris Hans, Adrian Dobra, and Mike West. “Shotgun stochastic search for “large p” regression”. In: *Journal of the American Statistical Association* 102.478 (2007), pp. 507–516.
- [161] Carrie A Davis et al. “The Encyclopedia of DNA elements (ENCODE): data portal update”. In: *Nucleic acids research* 46.D1 (2018), pp. D794–D801.
- [162] Gosia Trynka et al. “Disentangling the effects of colocalizing genomic annotations to functionally prioritize non-coding variants within complex-trait loci”. In: *The American Journal of Human Genetics* 97.1 (2015), pp. 139–152.
- [163] Jacob C Ulirsch et al. “Interrogation of human hematopoiesis at single-cell and single-variant resolution”. In: *Nature genetics* 51.4 (2019), p. 683.

- [164] Yoav Benjamini and Yosef Hochberg. “Controlling the false discovery rate: a practical and powerful approach to multiple testing”. In: *Journal of the Royal statistical society: series B (Methodological)* 57.1 (1995), pp. 289–300.
- [165] Haikun Wang et al. “The transcription factor Foxp1 is a critical negative regulator of the differentiation of follicular helper T cells”. In: *Nature immunology* 15.7 (2014), p. 667.
- [166] Jing He et al. “Circulating precursor CCR7loPD-1hi CXCR5+ CD4+ T cells indicate Tfh cell activity and promote antibody responses upon antigen reexposure”. In: *Immunity* 39.4 (2013), pp. 770–781.
- [167] Leonie Adam et al. “Follicular T Helper Cell Signatures in Primary Biliary Cholangitis and Primary Sclerosing Cholangitis”. In: *Hepatology communications* 2.9 (2018), pp. 1051–1063.
- [168] Philipp Rentzsch et al. “CADD: predicting the deleteriousness of variants throughout the human genome”. In: *Nucleic acids research* 47.D1 (2018), pp. D886–D894.
- [169] Marieke JH Coenen et al. “Common and different genetic background for rheumatoid arthritis and coeliac disease”. In: *Human molecular genetics* 18.21 (2009), pp. 4195–4203.
- [170] JA Todd et al. “Genetics of Type 1 Diabetes in Finland, Simmonds MJ, Heward JM, Gough SC, Wellcome Trust Case Control Consortium, Dunger DB, Wicker LS, Clayton DG: Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes”. In: *Nat Genet* 39.7 (2007), pp. 857–864.
- [171] Ynto S De Boer et al. “Genome-wide association study identifies variants associated with autoimmune hepatitis type 1”. In: *Gastroenterology* 147.2 (2014), pp. 443–452.
- [172] H. J. Westra et al. “Systematic identification of trans eQTLs as putative drivers of known disease associations”. In: *Nat Genet* 45.10 (2013), pp. 1238–43. ISSN: 1546-1718 (Electronic) 1061-4036 (Linking). DOI: 10.1038/ng.2756. URL: <https://www.ncbi.nlm.nih.gov/pubmed/24013639>.
- [173] Alexandra Zhernakova et al. “Evolutionary and functional analysis of celiac risk loci reveals SH2B3 as a protective factor against bacterial infection”. In: *The American Journal of Human Genetics* 86.6 (2010), pp. 970–977.
- [174] Marwa Chaouali et al. “Association of STAT4, TGF β 1, SH2B3 and PTPN22 polymorphisms with autoimmune hepatitis”. In: *Experimental and molecular pathology* 105.3 (2018), pp. 279–284.
- [175] Subra Kugathasan et al. “Loci on 20q13 and 21q22 are associated with pediatric-onset inflammatory bowel disease”. In: *Nature genetics* 40.10 (2008), p. 1211.

- [176] GTEx Consortium et al. “The Genotype-Tissue Expression (GTEx) pilot analysis: multitissue gene regulation in humans”. In: *Science* 348.6235 (2015), pp. 648–660.
- [177] Alexis Battle et al. “Characterizing the genetic basis of transcriptome diversity through RNA-sequencing of 922 individuals”. In: *Genome research* 24.1 (2014), pp. 14–24.
- [178] MQ Zhang. “Statistical features of human exons and their flanking regions”. In: *Human molecular genetics* 7.5 (1998), pp. 919–932.
- [179] Mingqi Tan et al. “Lysophosphatidylcholine activates a novel PKD2-mediated signaling pathway that controls monocyte migration”. In: *Arteriosclerosis, thrombosis, and vascular biology* 29.9 (2009), pp. 1376–1382.
- [180] Xiaona Ge et al. “Angiotensin II directly triggers endothelial exocytosis via protein kinase C-dependent protein kinase D2 activation”. In: *Journal of pharmacological sciences* 105.2 (2007), pp. 168–176.
- [181] Xavier Messeguer et al. “PROMO: detection of known transcription regulatory elements using species-tailored searches”. In: *Bioinformatics* 18.2 (2002), pp. 333–334.
- [182] Chris Wallace et al. “Statistical colocalization of monocyte gene expression and genetic risk variants for type 1 diabetes”. In: *Human molecular genetics* 21.12 (2012), pp. 2815–2824.
- [183] Tsun-Po Yang et al. “Genevar: a database and Java application for the analysis and visualization of SNP-gene associations in eQTL studies”. In: *Bioinformatics* 26.19 (2010), pp. 2474–2476.
- [184] Anna L Dixon et al. “A genome-wide association study of global gene expression”. In: *Nature genetics* 39.10 (2007), p. 1202.
- [185] Miriam F Moffatt et al. “Genetic variants regulating ORMDL3 expression contribute to the risk of childhood asthma”. In: *Nature* 448.7152 (2007), p. 470.
- [186] Alexandra C Nica and Emmanouil T Dermitzakis. “Using gene expression to investigate the genetic basis of complex disorders”. In: *Human molecular genetics* 17.R2 (2008), R129–R134.
- [187] Vincent Plagnol et al. “Statistical independence of the colocalized association signals for type 1 diabetes and RPS26 gene expression on chromosome 12q13”. In: *Biostatistics* 10.2 (2008), pp. 327–334.
- [188] Chris Wallace. “Statistical testing of shared genetic control for potentially related traits”. In: *Genetic epidemiology* 37.8 (2013), pp. 802–813.

- [189] Claudia Giambartolomei et al. “Bayesian test for colocalisation between pairs of genetic association studies using summary statistics”. In: *PLoS genetics* 10.5 (2014), e1004383.
- [190] Jun Ding et al. “Gene expression in skin and lymphoblastoid cells: Refined statistical method reveals extensive overlap in cis-eQTL signals”. In: *The American Journal of Human Genetics* 87.6 (2010), pp. 779–789.
- [191] Alexander L Richards et al. “Schizophrenia susceptibility alleles are enriched for alleles that affect gene expression in adult human brain”. In: *Molecular psychiatry* 17.2 (2012), p. 193.
- [192] Jon Wakefield. “Bayes factors for genome-wide association studies: comparison with P-values”. In: *Genetic Epidemiology: The Official Publication of the International Genetic Epidemiology Society* 33.1 (2009), pp. 79–86.
- [193] Mary D Fortune et al. “Statistical colocalization of genetic risk variants for related autoimmune diseases in the context of common controls”. In: *Nature genetics* 47.7 (2015), p. 839.
- [194] Urmo Võsa et al. “Unraveling the polygenic architecture of complex traits using blood eQTL meta-analysis”. In: *bioRxiv* (2018), p. 447367.
- [195] Hendrik G Stunnenberg et al. “The International Human Epigenome Consortium: a blueprint for scientific collaboration and discovery”. In: *Cell* 167.5 (2016), pp. 1145–1149.
- [196] Lu Chen et al. “Genetic drivers of epigenetic and transcriptional variation in human immune cells”. In: *Cell* 167.5 (2016), pp. 1398–1414.
- [197] John Lonsdale et al. “The genotype-tissue expression (GTEx) project”. In: *Nature genetics* 45.6 (2013), p. 580.
- [198] Sarah Kim-Hellmuth et al. “Genetic regulatory effects modified by immune activation contribute to autoimmune disease associations”. In: *Nature communications* 8.1 (2017), p. 266.
- [199] Heather J Cordell et al. “International genome-wide meta-analysis identifies new primary biliary cirrhosis risk loci and targetable pathogenic pathways”. In: *Nature communications* 6 (2015), p. 8019.
- [200] Jonathan P Bradfield et al. “A genome-wide meta-analysis of six type 1 diabetes cohorts identifies multiple associated loci”. In: *PLoS genetics* 7.9 (2011), e1002293.
- [201] Gosia Trynka et al. “Dense genotyping identifies and localizes multiple common and rare variant association signals in celiac disease”. In: *Nature genetics* 43.12 (2011), p. 1193.

- [202] Ashley H Beecham et al. “Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis”. In: *Nature genetics* 45.11 (2013), p. 1353.
- [203] James Bentham et al. “Genetic association analyses implicate aberrant regulation of innate and adaptive immunity genes in the pathogenesis of systemic lupus erythematosus”. In: *Nature genetics* 47.12 (2015), p. 1457.
- [204] William J Astle et al. “The allelic landscape of human blood cell trait variation and links to common complex disease”. In: *Cell* 167.5 (2016), pp. 1415–1429.
- [205] Sharon A Matthews et al. “Unique functions for protein kinase D1 and protein kinase D2 in mammalian cells”. In: *Biochemical Journal* 432.1 (2010), pp. 153–163.
- [206] M Armacki et al. “A novel splice variant of calcium and integrin-binding protein 1 mediates protein kinase D2-stimulated tumour growth by regulating angiogenesis”. In: *Oncogene* 33.9 (2014), p. 1167.
- [207] Atsushi Irie et al. “Protein kinase D2 contributes to either IL-2 promoter regulation or induction of cell death upon TCR stimulation depending on its activity in Jurkat cells”. In: *International immunology* 18.12 (2006), pp. 1737–1747.
- [208] Kenneth L Rock et al. “Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules”. In: *Cell* 78.5 (1994), pp. 761–771.
- [209] Jian Zhang et al. “Cutting edge: regulation of T cell activation threshold by CD28 costimulation through targeting Cbl-b for ubiquitination”. In: *The Journal of Immunology* 169.5 (2002), pp. 2236–2240.
- [210] Melissa Hunter et al. “Survival of monocytes and macrophages and their role in health and disease”. In: *Frontiers in bioscience: a journal and virtual library* 14 (2009), p. 4079.
- [211] Guo Wei et al. “Activated Ets2 is required for persistent inflammatory responses in the motheaten viable model”. In: *The Journal of Immunology* 173.2 (2004), pp. 1374–1379.
- [212] Ioannis Panagoulas et al. “Transcription factor Ets-2 acts as a preinduction repressor of interleukin-2 (IL-2) transcription in naive T helper lymphocytes”. In: *Journal of Biological Chemistry* 291.52 (2016), pp. 26707–26721.
- [213] A. Battle et al. “Characterizing the genetic basis of transcriptome diversity through RNA-sequencing of 922 individuals”. In: *Genome Res* 24.1 (2014), pp. 14–24. ISSN: 1549-5469 (Electronic) 1088-9051 (Linking). DOI: 10.1101/gr.155192.113. URL: <https://www.ncbi.nlm.nih.gov/pubmed/24092820>.

- [214] B. P. Fairfax et al. “Genetics of gene expression in primary immune cells identifies cell type-specific master regulators and roles of HLA alleles”. In: *Nat Genet* 44.5 (2012), pp. 502–10. ISSN: 1546-1718 (Electronic) 1061-4036 (Linking). DOI: 10.1038/ng.2205. URL: <http://www.ncbi.nlm.nih.gov/pubmed/22446964>.
- [215] Tuuli Lappalainen et al. “Transcriptome and genome sequencing uncovers functional variation in humans”. In: *Nature* 501.7468 (2013), pp. 506–511.
- [216] Yan Ge et al. “UBASH3A mediates risk for type 1 diabetes through inhibition of T-cell receptor-induced NF- κ B signaling”. In: *Diabetes* (2017), db161023.
- [217] Yan Ge and Patrick Concannon. “Molecular-genetic characterization of common, noncoding UBASH3A variants associated with type 1 diabetes”. In: *European Journal of Human Genetics* (2018), p. 1.
- [218] Julie Devallière and Béatrice Charreau. “The adaptor Lnk (SH2B3): an emerging regulator in vascular cells and a link between immune and inflammatory signaling”. In: *Biochemical pharmacology* 82.10 (2011), pp. 1391–1402.
- [219] Robert J Crowder et al. “Dok-6, a Novel p62 Dok family member, promotes Ret-mediated neurite outgrowth”. In: *Journal of Biological Chemistry* 279.40 (2004), pp. 42072–42081.
- [220] Jose L Badano et al. “The ciliopathies: an emerging class of human genetic disorders”. In: *Annu. Rev. Genomics Hum. Genet.* 7 (2006), pp. 125–148.
- [221] Nicholas F LaRusso and Tetyana V Masyuk. “The role of cilia in the regulation of bile flow”. In: *Digestive Diseases* 29.1 (2011), pp. 6–12.
- [222] Jo Knight et al. “Using functional annotation for the empirical determination of Bayes Factors for genome-wide association study analysis”. In: *PLoS One* 6.4 (2011), e14808.
- [223] Jian Yang et al. “Conditional and joint multiple-SNP analysis of GWAS summary statistics identifies additional variants influencing complex traits”. In: *Nature genetics* 44.4 (2012), p. 369.
- [224] Claudia Giambartolomei et al. “A Bayesian framework for multiple trait colocalization from summary association statistics”. In: *Bioinformatics* 34.15 (2018), pp. 2538–2545.
- [225] Chris Wallace et al. “Dissection of a complex disease susceptibility region using a Bayesian stochastic search approach to fine mapping”. In: *PLoS genetics* 11.6 (2015).
- [226] Jason Lewis. “Pathological patterns of biliary disease”. In: *Clinical liver disease* 10.5 (2017), p. 107.

- [227] Alexander Dobin et al. “STAR: ultrafast universal RNA-seq aligner”. In: *Bioinformatics* 29.1 (2013), pp. 15–21.
- [228] Yang Liao, Gordon K Smyth, and Wei Shi. “featureCounts: an efficient general purpose program for assigning sequence reads to genomic features”. In: *Bioinformatics* 30.7 (2013), pp. 923–930.
- [229] Jeremy Davis-Turak et al. “Genomics pipelines and data integration: challenges and opportunities in the research setting”. In: *Expert review of molecular diagnostics* 17.3 (2017), pp. 225–237.
- [230] Michael I Love, Wolfgang Huber, and Simon Anders. “Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2”. In: *Genome biology* 15.12 (2014), p. 550.
- [231] Alexandre Fort et al. “MBV: a method to solve sample mislabeling and detect technical bias in large combined genotype and sequencing assay datasets”. In: *Bioinformatics* 33.12 (2017), pp. 1895–1897.
- [232] Franck Rapaport et al. “Comprehensive evaluation of differential gene expression analysis methods for RNA-seq data”. In: *Genome biology* 14.9 (2013), p. 3158.
- [233] Alicia Oshlack and Matthew J Wakefield. “Transcript length bias in RNA-seq data confounds systems biology”. In: *Biology direct* 4.1 (2009), p. 14.
- [234] Joseph K Pickrell et al. “Understanding mechanisms underlying human gene expression variation with RNA sequencing”. In: *Nature* 464.7289 (2010), p. 768.
- [235] Simon Anders and Wolfgang Huber. “Differential expression analysis for sequence count data”. In: *Genome biology* 11.10 (2010), R106.
- [236] Jüri Reimand et al. “g: Profiler—a web-based toolset for functional profiling of gene lists from large-scale experiments”. In: *Nucleic acids research* 35.suppl_2 (2007), W193–W200.
- [237] Carl A Anderson et al. “Data quality control in genetic case-control association studies”. In: *Nature protocols* 5.9 (2010), p. 1564.
- [238] Shane McCarthy et al. “A reference panel of 64,976 haplotypes for genotype imputation”. In: *Nature genetics* 48.10 (2016), p. 1279.
- [239] Jonathan RI Coleman et al. “Quality control, imputation and analysis of genome-wide genotyping data from the Illumina HumanCoreExome microarray”. In: *Briefings in functional genomics* 15.4 (2016), pp. 298–304.
- [240] Hao Zhao et al. “CrossMap: a versatile tool for coordinate conversion between genome assemblies”. In: *Bioinformatics* 30.7 (2013), pp. 1006–1007.

- [241] Olivier Delaneau et al. “A complete tool set for molecular QTL discovery and analysis”. In: *Nature communications* 8.1 (2017), pp. 1–7.
- [242] Halit Ongen et al. “Fast and efficient QTL mapper for thousands of molecular phenotypes”. In: *Bioinformatics* 32.10 (2015), pp. 1479–1485.
- [243] John D Storey and Robert Tibshirani. “Statistical significance for genomewide studies”. In: *Proceedings of the National Academy of Sciences* 100.16 (2003), pp. 9440–9445.
- [244] Timothée Flutre et al. “A statistical framework for joint eQTL analysis in multiple tissues”. In: *PLoS genetics* 9.5 (2013), e1003486.
- [245] Yingying Wei, Toyooki Tenzen, and Hongkai Ji. “Joint analysis of differential gene expression in multiple studies using correlation motifs”. In: *Biostatistics* 16.1 (2014), pp. 31–46.
- [246] Sarah M Urbut et al. “Flexible statistical methods for estimating and testing effects in genomic studies with multiple conditions”. In: *Nature genetics* 51.1 (2019), pp. 187–195.
- [247] Sarah Kim-Hellmuth et al. “Cell type specific genetic regulation of gene expression across human tissues”. In: *bioRxiv* (2019), p. 806117.
- [248] James C Lee et al. “Gene expression profiling of CD8+ T cells predicts prognosis in patients with Crohn disease and ulcerative colitis”. In: *The Journal of clinical investigation* 121.10 (2011), pp. 4170–4179.
- [249] Daniele Biasci et al. “A blood-based prognostic biomarker in inflammatory bowel disease”. In: *bioRxiv* (2019), p. 535153.
- [250] Y Kim et al. “A meta-analysis of gene expression quantitative trait loci in brain”. In: *Translational psychiatry* 4.10 (2014), e459–e459.
- [251] Katharina Schramm et al. “Mapping the genetic architecture of gene regulation in whole blood”. In: *PLoS One* 9.4 (2014).
- [252] Yong He et al. “Long noncoding RNAs: Novel insights into hepatocellular carcinoma”. In: *Cancer letters* 344.1 (2014), pp. 20–27.
- [253] Bodu Liu et al. “A cytoplasmic NF- κ B interacting long noncoding RNA blocks I κ B phosphorylation and suppresses breast cancer metastasis”. In: *Cancer cell* 27.3 (2015), pp. 370–381.
- [254] Pin Wang et al. “The STAT3-binding long noncoding RNA lnc-DC controls human dendritic cell differentiation”. In: *Science* 344.6181 (2014), pp. 310–313.

- [255] Charles F Spurlock et al. “Expression and functions of long noncoding RNAs during human T helper cell differentiation”. In: *Nature communications* 6.1 (2015), pp. 1–12.
- [256] Susan Carpenter et al. “A long noncoding RNA mediates both activation and repression of immune response genes”. In: *science* 341.6147 (2013), pp. 789–792.
- [257] Jinsoo Song et al. “PBMC and exosome-derived Hotair is a critical regulator and potent marker for rheumatoid arthritis”. In: *Clinical and experimental medicine* 15.1 (2015), pp. 121–126.
- [258] Ming-Chi Lu et al. “Increased expression of long noncoding RNAs LOC100652951 and LOC100506036 in T cells from patients with rheumatoid arthritis facilitates the inflammatory responses”. In: *Immunologic research* 64.2 (2016), pp. 576–583.
- [259] Qing-Lin Peng et al. “Transcriptomic profiling of long non-coding RNAs in dermatomyositis by microarray analysis”. In: *Scientific reports* 6 (2016), p. 32818.
- [260] Isis Ricaño-Ponce et al. “Refined mapping of autoimmune disease associated genetic variants with gene expression suggests an important role for non-coding RNAs”. In: *Journal of autoimmunity* 68 (2016), pp. 62–74.
- [261] Benjamin J Schmiedel et al. “Impact of genetic polymorphisms on human immune cell gene expression”. In: *Cell* 175.6 (2018), pp. 1701–1715.
- [262] Akinori Takaoka et al. “Integral role of IRF-5 in the gene induction programme activated by Toll-like receptors”. In: *Nature* 434.7030 (2005), pp. 243–249.
- [263] Betsy J Barnes et al. “Multiple regulatory domains of IRF-5 control activation, cellular localization, and induction of chemokines that mediate recruitment of T lymphocytes”. In: *Molecular and Cellular Biology* 22.16 (2002), pp. 5721–5740.
- [264] G Gathungu et al. “A two-marker haplotype in the IRF5 gene is associated with inflammatory bowel disease in a North American cohort”. In: *Genes & Immunity* 13.4 (2012), pp. 351–355.
- [265] Hannah Almuttaqi and Irina A Udalova. “Advances and challenges in targeting IRF5, a key regulator of inflammation”. In: *The FEBS journal* 286.9 (2019), pp. 1624–1637.
- [266] Antonio F Di Narzo et al. “Blood and intestine eQTLs from an anti-TNF-resistant Crohn’s disease cohort inform IBD genetic association loci”. In: *Clinical and translational gastroenterology* 7.6 (2016), e177.
- [267] Letizia Straniero et al. “The GBAP1 pseudogene acts as a ceRNA for the glucocerebrosidase gene GBA by sponging miR-22-3p”. In: *Scientific reports* 7.1 (2017), pp. 1–13.

- [268] S Pablo Sardi et al. “Augmenting CNS glucocerebrosidase activity as a therapeutic strategy for parkinsonism and other Gaucher-related synucleinopathies”. In: *Proceedings of the National Academy of Sciences* 110.9 (2013), pp. 3537–3542.
- [269] Jie Liu et al. “Decreased UBASH3A mRNA expression levels in peripheral blood mononuclear cells from patients with systemic lupus erythematosus”. In: *Inflammation* 38.5 (2015), pp. 1903–1910.
- [270] Rosana HCN Freitas and Carlos AM Fraga. “NF- κ B-IKK β pathway as a target for drug development: Realities, challenges and perspectives”. In: *Current drug targets* 19.16 (2018), pp. 1933–1942.
- [271] Jonggi Choi et al. “Aspirin use and the risk of cholangiocarcinoma”. In: *Hepatology* 64.3 (2016), pp. 785–796.
- [272] Jianping Xiong et al. “Aspirin use is associated with a reduced risk of cholangiocarcinoma: a systematic review and meta-analysis”. In: *Cancer management and research* 10 (2018), p. 4095.
- [273] Karl Egerer et al. “Circulating proteasomes are markers of cell damage and immunologic activity in autoimmune diseases.” In: *The Journal of rheumatology* 29.10 (2002), pp. 2045–2052.
- [274] Stephan U Sixt and Burkhardt Dahlmann. “Extracellular, circulating proteasomes and ubiquitin—incidence and relevance”. In: *Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease* 1782.12 (2008), pp. 817–823.
- [275] Thomas Egerer et al. “Tissue-specific up-regulation of the proteasome subunit β 5i (LMP7) in Sjögren’s syndrome”. In: *Arthritis & Rheumatism: Official Journal of the American College of Rheumatology* 54.5 (2006), pp. 1501–1508.
- [276] Sue Ellen Verbrugge et al. “Proteasome inhibitors as experimental therapeutics of autoimmune diseases”. In: *Arthritis research & therapy* 17.1 (2015), p. 17.
- [277] Michael Brychcy et al. “Anti-20S proteasome autoantibodies inhibit proteasome stimulation by proteasome activator PA28”. In: *Arthritis & Rheumatism: Official Journal of the American College of Rheumatology* 54.7 (2006), pp. 2175–2183.
- [278] Eugen Feist et al. “Proteasome alpha-type subunit C9 is a primary target of autoantibodies in sera of patients with myositis and systemic lupus erythematosus.” In: *The Journal of experimental medicine* 184.4 (1996), pp. 1313–1318.
- [279] Carsten Berges et al. “Proteasome inhibition suppresses essential immune functions of human CD4+ T cells”. In: *Immunology* 124.2 (2008), pp. 234–246.
- [280] JW Van der Heijden et al. “The proteasome inhibitor bortezomib inhibits the release of NFkappaB-inducible cytokines and induces apoptosis of activated T cells from rheumatoid arthritis patients”. In: *Clin Exp Rheumatol* 27.1 (2009), pp. 92–8.

- [281] Takuma Misawa et al. “Mutual inhibition between Prkd2 and Bcl6 controls T follicular helper cell differentiation”. In: *Science Immunology* 5.43 (2020).
- [282] Alba Torres et al. “ETS2 is a prostate basal cell marker and is highly expressed in prostate cancers aberrantly expressing p63”. In: *The Prostate* 78.12 (2018), pp. 896–904.
- [283] WD Xi et al. “Bioinformatics analysis of RNA-seq data revealed critical genes in colon adenocarcinoma”. In: *European Review for Medical and Pharmacological Sciences* 21.13 (2017), pp. 3012–3020.
- [284] Guang-Wei Zhang et al. “Down-regulation of ETS2 inhibits the invasion and metastasis of renal cell carcinoma cells by inducing EMT via the PI3K/Akt signaling pathway”. In: *Biomedicine & Pharmacotherapy* 104 (2018), pp. 119–126.
- [285] Osamu Tetsu and Frank McCormick. “ETS-targeted therapy: can it substitute for MEK inhibitors?” In: *Clinical and translational medicine* 6.1 (2017), pp. 1–9.
- [286] Clare Bycroft et al. “The UK Biobank resource with deep phenotyping and genomic data”. In: *Nature* 562.7726 (2018), pp. 203–209.
- [287] Gareth-Rhys Jones et al. “Sa1790—Multi-Parameter Data-Sets are Required to Identify the True Prevalence of Ibd: the Lothian IBD Registry (LIBDR)”. In: *Gastroenterology* 156.6 (2019), S–403.
- [288] Miles Parkes. “IBD BioResource: an open-access platform of 25 000 patients to accelerate research in Crohn’s and Colitis”. In: *Gut* 68.9 (2019), pp. 1537–1540.
- [289] Janine Meienberg et al. “Clinical sequencing: is WGS the better WES?” In: *Human genetics* 135.3 (2016), pp. 359–362.
- [290] Eric R Gamazon et al. “A gene-based association method for mapping traits using reference transcriptome data”. In: *Nature genetics* 47.9 (2015), p. 1091.
- [291] Alexander Gusev et al. “Integrative approaches for large-scale transcriptome-wide association studies”. In: *Nature genetics* 48.3 (2016), p. 245.
- [292] Alvaro N Barbeira et al. “Exploring the phenotypic consequences of tissue specific gene expression variation inferred from GWAS summary statistics”. In: *Nature communications* 9.1 (2018), pp. 1–20.
- [293] Michael Wainberg et al. “Opportunities and challenges for transcriptome-wide association studies”. In: *Nature genetics* 51.4 (2019), pp. 592–599.
- [294] Chris Wallace. “Eliciting priors and relaxing the single causal variant assumption in colocalisation analyses”. In: *PLoS genetics* 16.4 (2020), e1008720.
- [295] Nicholas Mancuso et al. “Probabilistic fine-mapping of transcriptome-wide association studies”. In: *Nature genetics* 51.4 (2019), pp. 675–682.

- [296] Hilary K Finucane et al. “Heritability enrichment of specifically expressed genes identifies disease-relevant tissues and cell types”. In: *Nature genetics* 50.4 (2018), pp. 621–629.
- [297] Alvaro N Barbeira et al. “Integrating predicted transcriptome from multiple tissues improves association detection”. In: *PLoS genetics* 15.1 (2019), e1007889.
- [298] Monique GP van der Wijst et al. “Single-cell RNA sequencing identifies celltype-specific cis-eQTLs and co-expression QTLs”. In: *Nature genetics* 50.4 (2018), pp. 493–497.
- [299] Anna SE Cuomo et al. “Single-cell RNA-sequencing of differentiating iPS cells reveals dynamic genetic effects on gene expression”. In: *Nature communications* 11.1 (2020), pp. 1–14.
- [300] Abhishek K Sarkar et al. “Discovery and characterization of variance QTLs in human induced pluripotent stem cells”. In: *PLoS genetics* 15.4 (2019).
- [301] Hyun Min Kang et al. “Multiplexed droplet single-cell RNA-sequencing using natural genetic variation”. In: *Nature biotechnology* 36.1 (2018), p. 89.
- [302] Monique GP van der Wijst et al. “The single-cell eQTLGen consortium”. In: *Elife* 9 (2020), e52155.